BioSpace News Archive

-- Significance of 30% overall response rate (ORR), 6% complete responses (CR), durability and favorable safety data from KEYNOTE-695 Phase 2b trial discussed by Key Opinion Leaders (KOLs) specializing in melanoma treatment --

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the final results from its PLX9486 + sunitinib Phase 1/2 study in patients with advanced gastrointestinal stromal tumors (GIST).

Tel Aviv University and The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center announced today that, for the first time in humans, two key biological hallmarks of aging, telomere length shortening and accumulation of senescent cells, can be reversed, according to a new study.

Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effecto

Research led by investigators at the Children’s Hospital at Montefiore, Albert Einstein College of Medicine and Yale School of Medicine, identifies symptoms that can predict how severely children will be affected by COVID-19.

4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its first software-as-a-medical-device solution

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.

Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to humans.

Bioventus, a leader in Solutions For Innovative Healing, received authorization to proceed under its investigational new drug (IND) application from the US Food and Drug Administration (FDA), allowing it to proceed to clinical trials of PTP-001

Geisinger has been selected as one of seven finalists in the Centers for Medicare & Medicaid (CMS) Artificial Intelligence Health Outcomes Challenge.